The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
0.34375p trades are buys I believe.
Massive acreage.
Looking good.
Hello.
Hic!
Jackbal.
Now the Parsortix PC-1, the version that is authorised for use by the FDA in the United States for catching Breast Cancer circulating tumour cells for analysis for has been available since roughly September 2022 I think we should get some sales figures in the next results. I think the PC-1 versions are about $50,000 each? Although the RNS to say the FDA clearance was dated 25/05/2022 obviously the paperwork with the machine etc. would have taken some months to sort out so I'm assuming September 2022 was when they became available. That would be very roughly 18 months on the market.
https://angleplc.com/the-parsortix-pc1-system/
Also the amount of cassettes sold would be good (@around $300 each). These are used both with the PC-1 version and the PR-1 version which is for research only. This version costs about $40,000 as I understand it.
The results which should be around 25th April should be extremely interesting. News of some sort of deal with one of the CtDNA analysis Co's would be greatly appreciated!! Also sales of the new assays will be interesting and of course news on the HER2 contract with Bioview which could involve a tie up with a large Pharma Co...................
All IMHO.
Miavoce.
“Around $300 per 1 use cassette how do we know how they have been doing?”
EC that’s a fair point but I lean towards if sales are healthy why not disclose to mkt to improve valuation.
The valuation is the collateral for a company that presently relies on funding so why not uphold it?
Wouldn’t make sense holding back positive stuff like that in these circumstances
=================================================
That sort of information is only disclosed in the results which should be around 21/4/2024.
Only very important information which might affect the bottom line is announced in RNS's between the results.
Do they!
Angle PLC Interim Results for the period ended 30 June 2023.
"-- Installed base of Parsortix(R) systems increased to over 290 with cumulative samples processed of 192,000 as at 30 June 2023."
=============
Over 190 machines as at 30th June 2023.
So almost 9 months ago. How many machines now? How many disposable cassettes now?
Do any of the 50 plus Co's IN THE WORLD that offer DNA analysis of blood want to add the analysis of the Circulating Tumour Cells (CTC's)? Do they want to offer a re-badged Parsortix machine to their clients so they catch the CTC's and do the additional analysis to get the full picture? They should want to as it would increase sales and give their clients all the available information (CtDNA analysis of blood plus DNA analysis of the CTC's = the complete picture).
All IMHO.
Around $300 per 1 use cassette how do we know how they have been doing?
I'm sure the shorters on here will come up with something from thin air.
With 190 machines out there in the World a load of cassettes may be being used etc....
All IMHO.
Good to me. Took a chance and did not sell any before the results.
CWWX
Blue in the US
=======================
Just gone blue here too!!!
Nice to be paid $7 billion in advance. Presumably they get interest on that!
Only down 0.82% now.
Turn blue, you know you want to!
The sp has been here 3 or 4 times before in the last 2 years. Nice 30% plus.
Roche or some such their sp will be back to over 30p in 30 mins.............
Angle Plc have the tech to catch circulating tumour cells for analysis. Most of the Companies that currently offer CtDNA blood analysis don't offer the same for the CTC's simply because they do not have a system that can catch the CCTC's, or at least ones that are LIVE, intact and not contaminated by the very system used to catch them!!
Some sort of deals must happen.
All IMHO.
Only 0.5% down now. Nearly there!!
Exellent!.
Incredible!
To guide treatment decisions. As you can read they are using "Illumina technology" to look for "actionable DNA" which can be targeted by modern drugs. See here:-
https://www.bbc.co.uk/news/uk-wales-65377533
and
https://www.bbc.co.uk/news/health-68624334
In Angle's RNS announcements of 4th and 20th January Angle have discovered that both their study (RNS of 4th Jan) AND other previous studies (RNS dated 20th Jan) showed actionable DNA is sometimes found only in the circulating tumour cells (CTC's) and NOT in the blood CtDNA!! Companies like Illumina do not have a system that can catch LIVE intact cancerous tumour cells to analyse. Angle of course do. So what do you thing they will do next???
https://www.youtube.com/watch?v=cnQ6M05BiBY
All IMHO
Mutational signature profiles, and therapeutic targets compatible with those found in matching primary tumor samples.".
==========
What is genomic heterogeneity?
A term that describes when different gene mutations (changes) cause the same disease or condition.
=========
So the circulationg tumour cells Parsortix caught were the best samples and most like the primary tumour.......... better that Cellsearch.
========================
Genomics
Volume 114, Issue 6, November 2022, 110500
https://www.sciencedirect.com/science/article/pii/S0888754322002452
================
All IMHO.